ProCE Banner Activity

ANDES: Generic Fixed-Dose DRV/RTV in Combination With 3TC vs 3TC/TDF for Initial HIV Treatment

Slideset Download
Conference Coverage
Dual therapy was well tolerated and demonstrated noninferior efficacy vs triple therapy as first-line ART in this open-label, randomized trial conducted in Argentina.

Released: August 05, 2022

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare


IAS 2021

ProCE Banner